Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.

Anticancer Drugs · 2020 · PMC7028287 · PMID 31977567

Europe PMC DOI

hedged sentence

0.4100

closest p · 8.2× alpha

0.4100

boldest claim

The sentences

did not reach statistical significanceP = 0.41not close (p > 0.1)

2 ) showed a clear benefit for lanreotide autogel/depot 120 mg in each NLR subgroup (hazard ratios from 0.23 to 0.75, P ≤ 0.05) except for the middle NLR tertile, in which the benefit did not reach statistical significance [hazard ratio = 0.75 (95% CI: 0.38, 1.48), P = 0.41].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.